The Association of Biotechnology Companies BioForum launches the #polishbiotech online database as the largest association of biotech companies in Poland.
We are the first point of contact for entrepreneurs in the biotechnology industry and we constantly support the Polish biotechnology community 👩🔬 👨🔬
SIGN UP HERE 👇👇👇
"*" indicates required fields
Cellis
+ business areaBioPharma R&D+Services
2019 - 157,000 PLN
2021 - 43,300,000 PLN
2022 - 22,700,000 PLN
2023 - 214,800 PLN
2024 - 86,600 PLN
2024 - 11
2019 - 71,200 PLN
2021 - 215,400 PLN
2022 - 210,000 PLN
2023 - 35,900 PLN
2024 - 27,800 PLN
Cellis is a European biotech company, with a focus in cell-based oncology therapy. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC) for the treatment of solid tumors. MDC is based on the ground-breaking discovery of the biologic TRAIN mechanism, which enables efficient and highly targeted delivery of a wide range of active moieties and compounds directly into the cytoplasm of cancer cells. As a result, cancer cells are killed and tumor masses shrink. MDC also changes the tumor microenvironment creating immune resistance to cancer growth. Preparation is underway to progress our technology to the first in human clinical trials in Q3 2024.